NCT04898985 (LLST-Cells) is a clinical trial of ImmunoSEQ in Covid-19, sponsored by Larry Saltzman, MD.

Who is sponsoring NCT04898985?

NCT04898985 is sponsored by Larry Saltzman, MD.

What drugs are being tested in NCT04898985?

Interventions in NCT04898985: ImmunoSEQ.

Is NCT04898985 still recruiting?

NCT04898985 is currently suspended. Last updated 17 August 2022.

Last reviewed 2022-08-17 · How we verify

NCT04898985: LLST-Cells

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19

Suspended Last updated 17 August 2022

What this trial tests

trial testing ImmunoSEQ in Covid-19 in 1,000 participants. Suspended.

Timeline

20 May 2021

Primary endpoint
20 May 2031

20 May 2031

Quick facts

Lead sponsor	Larry Saltzman, MD
Status	Suspended
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	20 May 2021
Primary completion	20 May 2031
Estimated completion	20 May 2031
Sites	1 location across United States

Drugs / interventions tested

ImmunoSEQ

Conditions studied

Covid-19 — all drugs for Covid-19 →

Sponsor

Larry Saltzman, MD

Who can join

Eligibility, any sex, with Covid-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in the LLS T-cells, Blood Cancer and COVID-19 Clinical Research Study. They will be followed for at least ten years (in the COVID-19 Registry). In addition, 500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled the LLS T-cells, Blood Cancer and COVID-19 Clinical Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies.
Greenberger LM, Saltzman LA, Gruenbaum LM, Xu J, et al · · 2022 · cited 18× · PMID 36074641 · DOI 10.1158/2643-3230.bcd-22-0077

Verify or expand the search:

Other recruiting trials for Covid-19

Currently open trials in the same condition.

NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting
NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04898985 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Larry Saltzman, MD
Last refreshed: 17 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04898985.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing